REG - Haleon PLC - Transaction in Own Shares

HALEONAnnouncement

15/04/2025 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250415:nRSO9848Ea&default-theme=true

RNS Number : 9848E  Haleon PLC  15 April 2025

 Haleon plc: Transaction in own shares

 Purchase of own shares

 15 April 2025: Haleon plc (the Company or Haleon) today announces the purchase
 of the following number of ordinary shares of £0.01 each in the Company (the
 Shares) for cancellation under its share buyback programme announced on 28
 March 2025 (the Buyback Programme).

 Date of purchase:                                  14 April 2025
 Number of Shares purchased:                        865,652
 Lowest price paid per share (p):                   £ 3.7420
 Highest price paid per share (p):                  £ 3.7960
 Volume weighted average price paid per share (p):  £ 3.7657

Date of purchase:                                  14 April 2025
 Number of Shares purchased:                        865,652
 Lowest price paid per share (p):                   £ 3.7420
 Highest price paid per share (p):                  £ 3.7960
 Volume weighted average price paid per share (p):  £ 3.7657

 Following the settlement of the above, the Company's registered share capital
 is 9,029,557,071 ordinary shares of £0.01 each, of which 4,080,205 are held
 as treasury shares. Therefore, the number of ordinary shares with voting
 rights is 9,025,476,866 and this figure may be used by shareholders to
 determine if they are required to notify their interest, or a change to their
 interest, in Haleon under the FCA's Disclosure Guidance and Transparency
 Rules.

 In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it
 applies in the UK (the Market Abuse Regulation), a full breakdown of the
 individual trades is available at the link below:

 http://www.rns-pdf.londonstockexchange.com/rns/9848E_1-2025-4-14.pdf
 (http://www.rns-pdf.londonstockexchange.com/rns/9848E_1-2025-4-14.pdf)

 This announcement does not constitute, or form part of, an offer or any
 solicitation of an offer for securities in any jurisdiction.

 This announcement and individual trade breakdown will also be available on the
 Company's website at: www.haleon.com/investors.

 Enquiries

 Investors
 Media

 Jo Russell       +44 7787
 392441                                 Zoë
 Bird              +44 7736 746167

 Rakesh Patel       +44 7552
 484646                             Victoria
 Durman   +44 7894 505730

 Emma White     +44 7823 523562

 Email: investor-relations@haleon.com
                          Email:
 corporate.media@haleon.com

 About Haleon

 Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose
 to deliver better everyday health with humanity. Haleon's product portfolio
 spans five major categories - Oral Health, Pain Relief, Respiratory Health,
 Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its
 long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu,
 Otrivin, Polident, parodontax and Centrum - are built on trusted science,
 innovation and deep human understanding.

 For more information, please visit www.haleon.com.

Haleon plc: Transaction in own shares

 Purchase of own shares

 15 April 2025: Haleon plc (the Company or Haleon) today announces the purchase
 of the following number of ordinary shares of £0.01 each in the Company (the
 Shares) for cancellation under its share buyback programme announced on 28
 March 2025 (the Buyback Programme).

 Date of purchase:                                  14 April 2025
 Number of Shares purchased:                        865,652
 Lowest price paid per share (p):                   £ 3.7420
 Highest price paid per share (p):                  £ 3.7960
 Volume weighted average price paid per share (p):  £ 3.7657

Date of purchase:                                  14 April 2025
 Number of Shares purchased:                        865,652
 Lowest price paid per share (p):                   £ 3.7420
 Highest price paid per share (p):                  £ 3.7960
 Volume weighted average price paid per share (p):  £ 3.7657

 

 Following the settlement of the above, the Company's registered share capital
 is 9,029,557,071 ordinary shares of £0.01 each, of which 4,080,205 are held
 as treasury shares. Therefore, the number of ordinary shares with voting
 rights is 9,025,476,866 and this figure may be used by shareholders to
 determine if they are required to notify their interest, or a change to their
 interest, in Haleon under the FCA's Disclosure Guidance and Transparency
 Rules.

 In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it
 applies in the UK (the Market Abuse Regulation), a full breakdown of the
 individual trades is available at the link below:

 http://www.rns-pdf.londonstockexchange.com/rns/9848E_1-2025-4-14.pdf
 (http://www.rns-pdf.londonstockexchange.com/rns/9848E_1-2025-4-14.pdf)

 This announcement does not constitute, or form part of, an offer or any
 solicitation of an offer for securities in any jurisdiction.

 This announcement and individual trade breakdown will also be available on the
 Company's website at: www.haleon.com/investors.

 Enquiries

 Investors
 Media

 Jo Russell       +44 7787
 392441                                 Zoë
 Bird              +44 7736 746167

 Rakesh Patel       +44 7552
 484646                             Victoria
 Durman   +44 7894 505730

 Emma White     +44 7823 523562

 Email: investor-relations@haleon.com
                          Email:
 corporate.media@haleon.com

 About Haleon

 Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose
 to deliver better everyday health with humanity. Haleon's product portfolio
 spans five major categories - Oral Health, Pain Relief, Respiratory Health,
 Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its
 long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu,
 Otrivin, Polident, parodontax and Centrum - are built on trusted science,
 innovation and deep human understanding.

 For more information, please visit www.haleon.com.

 Haleon plc: Transaction in own shares

 Purchase of own shares

 15 April 2025: Haleon plc (the Company or Haleon) today announces the purchase
 of the following number of ordinary shares of £0.01 each in the Company (the
 Shares) for cancellation under its share buyback programme announced on 28
 March 2025 (the Buyback Programme).

 Date of purchase:                                  14 April 2025
 Number of Shares purchased:                        865,652
 Lowest price paid per share (p):                   £ 3.7420
 Highest price paid per share (p):                  £ 3.7960
 Volume weighted average price paid per share (p):  £ 3.7657

 Date of purchase:                                  14 April 2025
 Number of Shares purchased:                        865,652
 Lowest price paid per share (p):                   £ 3.7420
 Highest price paid per share (p):                  £ 3.7960
 Volume weighted average price paid per share (p):  £ 3.7657

 Following the settlement of the above, the Company's registered share capital
 is 9,029,557,071 ordinary shares of £0.01 each, of which 4,080,205 are held
 as treasury shares. Therefore, the number of ordinary shares with voting
 rights is 9,025,476,866 and this figure may be used by shareholders to
 determine if they are required to notify their interest, or a change to their
 interest, in Haleon under the FCA's Disclosure Guidance and Transparency
 Rules.

 In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it
 applies in the UK (the Market Abuse Regulation), a full breakdown of the
 individual trades is available at the link below:

 http://www.rns-pdf.londonstockexchange.com/rns/9848E_1-2025-4-14.pdf
 (http://www.rns-pdf.londonstockexchange.com/rns/9848E_1-2025-4-14.pdf)

 This announcement does not constitute, or form part of, an offer or any
 solicitation of an offer for securities in any jurisdiction.

 This announcement and individual trade breakdown will also be available on the
 Company's website at: www.haleon.com/investors.

 Enquiries

 Investors
 Media

 Jo Russell       +44 7787
 392441                                 Zoë
 Bird              +44 7736 746167

 Rakesh Patel       +44 7552
 484646                             Victoria
 Durman   +44 7894 505730

 Emma White     +44 7823 523562

 Email: investor-relations@haleon.com
                          Email:
 corporate.media@haleon.com

 About Haleon

 Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose
 to deliver better everyday health with humanity. Haleon's product portfolio
 spans five major categories - Oral Health, Pain Relief, Respiratory Health,
 Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its
 long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu,
 Otrivin, Polident, parodontax and Centrum - are built on trusted science,
 innovation and deep human understanding.

 For more information, please visit www.haleon.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  POSDZLFFEZLZBBD